Arch Venture Corp

Latest statistics and disclosures from ARCH Venture Management's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Arch Venture Corp consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for ARCH Venture Management

ARCH Venture Management holds 9 positions in its portfolio as reported in the June 2024 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Beam Therapeutics (BEAM) 47.9 $128M NEW 5.4M 23.43
 View chart
Rapport Therapeutics (RAPP) 32.6 $87M NEW 3.7M 23.26
 View chart
Erasca (ERAS) 9.8 $26M 11M 2.36
 View chart
Verve Therapeutics (VERV) 3.7 $9.8M 2.0M 4.88
 View chart
Gossamer Bio (GOSS) 2.7 $7.3M 8.1M 0.90
 View chart
Q32 Bio (QTTB) 2.2 $5.8M 321k 17.95
 View chart
Unity Biotechnology Com New (UBX) 0.5 $1.4M 1.0M 1.35
 View chart
Singular Genomics Systems Com New (OMIC) 0.4 $1.1M NEW 127k 8.45
 View chart
Cero Therapeutics Holdings Class A Com (CERO) 0.2 $432k 1.4M 0.30
 View chart

Past Filings by ARCH Venture Management

SEC 13F filings are viewable for ARCH Venture Management going back to 2018

View all past filings